Storyboard

Hims & Hers Stock Hits 3-Year High After Announcing $199 Weight-Loss Alternative

Shares of telehealth company Hims & Hers Health closed at a three-year high Monday after the company announced a weight-loss treatment starting at $199 a month that will compete with Novo Nordisk’s Wegovy and Ozempic and enter the weight-loss market amid a shortage of branded treatments.

Avatar - Forbes
Curated by
Forbes
    • Wegovy
    • Ozempic
    • Novo Nordisk
    • Diabetes
    • Eli Lilly
Hims & Hers Stock Hits 3-Year High After Announcing $199 Weight-Loss Alternative
Continue to read
3 stories in this Storyboard
    Hims & Hers Stock Hits 3-Year High After Announcing $199 Weight-Loss Alternative To Wegovy

    Hims & Hers Stock Hits 3-Year High After Announcing $199 Weight-Loss Alternative To Wegovy

    Forbes - Antonio Pequeño IV

    Shares of telehealth company Hims & Hers Health closed at a three-year high Monday after the company announced a weight-loss treatment starting at $199 a month that will compete with Novo Nordisk’s Wegovy and Ozempic and enter the weight-loss market amid a shortage of branded treatments. Key …

    MORE FROM FORBES

Storyboard

Hims & Hers Stock Hits 3-Year High After Announcing $199 Weight-Loss Alternative

Avatar - Forbes
Curated by
Forbes

Related articles

  • Baby’s Grandfather Acts Strange With Her, Mom Installs Video Camera To Find Out

    Baby’s Grandfather Acts Strange With Her, Mom Installs Video Camera To Find Out

    By LittleThings
See more

More stories from Wegovy

See more stories in
Wegovy

More stories from Ozempic

See more stories in
Ozempic